These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 30759753)

  • 21. Radiopharmaceuticals for Palliation of Bone Pain in Patients with Castration-resistant Prostate Cancer Metastatic to Bone: A Systematic Review.
    Jong JM; Oprea-Lager DE; Hooft L; de Klerk JM; Bloemendal HJ; Verheul HM; Hoekstra OS; van den Eertwegh AJ
    Eur Urol; 2016 Sep; 70(3):416-26. PubMed ID: 26391636
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Abass Alavi: A giant in Nuclear Medicine turns 80 and is still going strong!
    Høilund-Carlsen PF
    Hell J Nucl Med; 2018; 21(1):85-87. PubMed ID: 29550853
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Use of radionuclides in therapy].
    Vucina J; Han R
    Med Pregl; 2001; 54(5-6):245-50. PubMed ID: 11759220
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Radiometals for imaging and theranostics, current production, and future perspectives.
    Mikolajczak R; van der Meulen NP; Lapi SE
    J Labelled Comp Radiopharm; 2019 Aug; 62(10):615-634. PubMed ID: 31137083
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Labelling of
    Iori M; Capponi PC; Rubagotti S; Esposizione LR; Seemann J; Pitzschler R; Dreger T; Formisano D; Grassi E; Fioroni F; Versari A; Asti M
    Contrast Media Mol Imaging; 2017; 2017():8160134. PubMed ID: 29097938
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Availability of yttrium-90 from strontium-90: a nuclear medicine perspective.
    Chakravarty R; Dash A; Pillai MR
    Cancer Biother Radiopharm; 2012 Dec; 27(10):621-41. PubMed ID: 23009585
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Electron- and positron-emitting radiolanthanides for therapy: aspects of dosimetry and production.
    Uusijärvi H; Bernhardt P; Rösch F; Maecke HR; Forssell-Aronsson E
    J Nucl Med; 2006 May; 47(5):807-14. PubMed ID: 16644751
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bisphosphonates as radionuclide carriers for imaging or systemic therapy.
    Palma E; Correia JD; Campello MP; Santos I
    Mol Biosyst; 2011 Nov; 7(11):2950-66. PubMed ID: 21879109
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Trends of Radiotheranostics Research].
    Hosono M
    Gan To Kagaku Ryoho; 2022 Aug; 49(8):809-812. PubMed ID: 36046961
    [TBL] [Abstract][Full Text] [Related]  

  • 30. New ways of insulin delivery.
    Heinemann L
    Int J Clin Pract Suppl; 2011 Feb; (170):31-46. PubMed ID: 21323811
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dose Deposits from 90Y, 177Lu, 111In, and 161Tb in Micrometastases of Various Sizes: Implications for Radiopharmaceutical Therapy.
    Hindié E; Zanotti-Fregonara P; Quinto MA; Morgat C; Champion C
    J Nucl Med; 2016 May; 57(5):759-64. PubMed ID: 26912441
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Theranostic Perspectives in Prostate Cancer with the Gastrin-Releasing Peptide Receptor Antagonist NeoBOMB1: Preclinical and First Clinical Results.
    Nock BA; Kaloudi A; Lymperis E; Giarika A; Kulkarni HR; Klette I; Singh A; Krenning EP; de Jong M; Maina T; Baum RP
    J Nucl Med; 2017 Jan; 58(1):75-80. PubMed ID: 27493272
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeted delivery of radiolabeled imaging and therapeutic agents: bifunctional radiopharmaceuticals.
    Saji H
    Crit Rev Ther Drug Carrier Syst; 1999; 16(2):209-44. PubMed ID: 10706443
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Somatostatin receptors as targets for nuclear medicine imaging and radionuclide treatment.
    Maecke HR; Reubi JC
    J Nucl Med; 2011 Jun; 52(6):841-4. PubMed ID: 21571797
    [TBL] [Abstract][Full Text] [Related]  

  • 35. α- Versus β-Emitting Radionuclides for Pretargeted Radioimmunotherapy of Carcinoembryonic Antigen-Expressing Human Colon Cancer Xenografts.
    Heskamp S; Hernandez R; Molkenboer-Kuenen JDM; Essler M; Bruchertseifer F; Morgenstern A; Steenbergen EJ; Cai W; Seidl C; McBride WJ; Goldenberg DM; Boerman OC
    J Nucl Med; 2017 Jun; 58(6):926-933. PubMed ID: 28232604
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of beta-absorbed fractions in a mouse model for 90Y, 188Re, 166Ho, 149Pm, 64Cu, and 177Lu radionuclides.
    Miller WH; Hartmann-Siantar C; Fisher D; Descalle MA; Daly T; Lehmann J; Lewis MR; Hoffman T; Smith J; Situ PD; Volkert WA
    Cancer Biother Radiopharm; 2005 Aug; 20(4):436-49. PubMed ID: 16114992
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmaceutical and clinical development of phosphonate-based radiopharmaceuticals for the targeted treatment of bone metastases.
    Lange R; Ter Heine R; Knapp RF; de Klerk JM; Bloemendal HJ; Hendrikse NH
    Bone; 2016 Oct; 91():159-79. PubMed ID: 27496068
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The use of radioisotopes for palliation of metastatic bone pain.
    Gkialas I; Iordanidou L; Galanakis I; Giannopoulos S
    J BUON; 2008; 13(2):177-83. PubMed ID: 18555462
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Global Trends Survey for Targeted Radionuclide Therapy].
    Hanaoka K; Maeda T; Miyaji N; Sakaguchi K; Yoneyama H; Ogawa M; Tsushima H
    Nihon Hoshasen Gijutsu Gakkai Zasshi; 2018 Dec; 74(12):1443-1448. PubMed ID: 30568095
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Macrocyclic complexes of scandium radionuclides as precursors for diagnostic and therapeutic radiopharmaceuticals.
    Majkowska-Pilip A; Bilewicz A
    J Inorg Biochem; 2011 Feb; 105(2):313-20. PubMed ID: 21194633
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.